AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform... Show more
ANTX is expected to report earnings to fall 29.03% to -21 cents per share on April 01
Q4'25
Est.
$-0.22
Q3'25
Est.
$-0.31
Q2'25
Beat
by $0.10
Q1'25
Missed
by $0.10
Q4'24
Beat
by $0.02
The last earnings report on November 12 showed earnings per share of -31 cents, beating the estimate of -31 cents. With 40.72K shares outstanding, the current market capitalization sits at 30.88M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ANTX showed earnings on November 12, 2025. You can read more about the earnings report here.